Intellectia LogoIntellectia
Product
Resources
Markets
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
Crypto Technical Analysis
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Earnings Trading
Stock Chart Patterns
Daytrading Center

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks
Pricing
Start for Free
  1. Home
  2. >
  3. Stock
  4. >
  5. MIRM
stocks logo

MIRM

-
Add to WatchlistAdvanced Chart
$
0.000
0.000(0.000%)
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q2
FY2025Q3
FY2025Q4
105.77M
+35.82%
--
--
110.21M
+21.95%
--
--
116.17M
+16.85%
--
--
Estimates Revision
The market is revising Upward the revenue expectations for Mirum Pharmaceuticals, Inc. (MIRM) for FY2025, with the revenue forecasts being adjusted by 2.29% over the past three months. During the same period, the stock price has changed by 28.36%.
Revenue Estimates for FY2025
Revise Upward
up Image
+2.29%
In Past 3 Month
Stock Price
Go Up
up Image
+28.36%
In Past 3 Month
8 Analyst Rating
up Image0
Wall Street analysts forecast MIRM stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for MIRM is 69.13 USD with a low forecast of 53.00 USD and a high forecast of 77.00  USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
8 Buy
0 Hold
0 Sell
Strong Buy
up Image0
Current: 50.470
sliders
Low
53.00
Averages
69.13
High
77.00
up Image0
Current: 50.470
sliders
Low
53.00
Averages
69.13
High
77.00
H.C. Wainwright
NULL -> Buy
initiated
$73
2025-05-19
Reason
H.C. Wainwright
Price Target
$73
2025-05-19
initiated
NULL -> Buy
Reason
Raymond James
Ryan Deschner
Strong Buy
maintain
$73 -> $77
2025-05-13
Reason
Raymond James
Ryan Deschner
Price Target
$73 -> $77
2025-05-13
maintain
Strong Buy
Reason
Raymond James analyst Ryan Deschner raised the firm's price target on Mirum Pharmaceuticals to $77 from $73 and keeps a Strong Buy rating on the shares. The price target increase is driven by bile acid portfolio and Livmarli net sales in addition to raised guidance for fiscal 2025, the analyst tells investors in a research note.
Citi
Buy
maintain
$72
2025-05-12
Reason
Citi
Price Target
$72
2025-05-12
maintain
Buy
Reason
Citizens JMP
Jonathan Wolleben
Outperform
maintain
$74 -> $76
2025-05-09
Reason
Citizens JMP
Jonathan Wolleben
Price Target
$74 -> $76
2025-05-09
maintain
Outperform
Reason
HC Wainwright & Co.
Ed Arce
Strong Buy
Maintains
$66 → $72
2025-02-28
Reason
HC Wainwright & Co.
Ed Arce
Price Target
$66 → $72
2025-02-28
Maintains
Strong Buy
Reason
Baird
Brian Skorney
Buy
Maintains
$50 → $55
2025-02-27
Reason
Baird
Brian Skorney
Price Target
$50 → $55
2025-02-27
Maintains
Buy
Reason
See All Ratings

Valuation Metrics

The current forward P/E ratio for Mirum Pharmaceuticals Inc (MIRM.O) is -43.04, compared to its 5-year average forward P/E of -16.74. For a more detailed relative valuation and DCF analysis to assess Mirum Pharmaceuticals Inc 's fair value, click here.
    Forward PE
    Forward EV/EBITDA
    Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-16.74
Current PE
-43.04
Overvalued PE
-0.32
Undervalued PE
-33.16

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-18.64
Current EV/EBITDA
-79.34
Overvalued EV/EBITDA
5.45
Undervalued EV/EBITDA
-42.73

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
Fair
5Y Average PS
7.22
Current PS
5.43
Overvalued PS
12.51
Undervalued PS
1.94

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %

Trading Trends

    Insider
    Hedge Fund
    Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought

MIRM News & Events

Events Timeline

(ET)
2025-05-19
09:07:47
Mirum Pharmaceuticals appoints Doug Sheehy as Chief Legal Officer
select
2025-05-07 (ET)
2025-05-07
16:22:33
Mirum Pharmaceuticals reports Q1 EPS (30c), consensus (27c)
select
2025-04-14 (ET)
2025-04-14
09:20:05
Mirum Pharmaceuticals receives FDA approval for Livmarli tablet formulation
select
Sign Up For More Events
Sign Up For More Events

News

Preview
8.0
06-24NASDAQ.COM
Interesting MIRM Put And Call Options For August 15th
  • Put Contract Analysis: An investor can sell a put contract at a $50.00 strike price for a premium of $1.00, effectively lowering their cost basis to $49.00, which is attractive compared to the current stock price of $50.36. There is a 56% chance that the contract may expire worthless, providing a potential 2.00% return on cash commitment.

  • Call Contract Strategy: Purchasing shares at $50.36 and selling a covered call at a $55.00 strike could yield a total return of 9.41% if the stock is called away by expiration. The odds of the call expiring worthless are 62%, allowing the investor to keep both the shares and the premium collected, resulting in a potential YieldBoost of 0.20%.

Preview
5.0
06-11Newsfilter
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
  • Inducement Awards Granted: Mirum Pharmaceuticals announced the granting of inducement awards to 10 new employees, including non-qualified stock options for 115,620 shares and 57,740 restricted stock units (RSUs), as part of their 2020 Inducement Plan.

  • Company Overview: Mirum Pharmaceuticals focuses on treating rare diseases with three approved medications and is advancing its pipeline with investigational treatments, including studies for cholestatic pruritus and Fragile X syndrome.

Preview
4.0
05-14Benzinga
Raymond James Maintains Strong Buy on Mirum Pharmaceuticals, Raises Price Target to $77
  • Real-time Intelligence for Traders: Benzinga Pro offers the fastest news alerts and exclusive stories to help traders make informed decisions in the stock market.

  • Community of Serious Traders: Over 10,000 traders are part of the Benzinga Pro community, benefiting from accurate market intelligence and insights.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Mirum Pharmaceuticals Inc (MIRM) stock price today?

The current price of MIRM is 50.47 USD — it has increased 0.34 % in the last trading day.

arrow icon

What is Mirum Pharmaceuticals Inc (MIRM)'s business?

Mirum Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the treatment of rare diseases affecting children and adults. It has three medicines: LIVMARLI (maralixibat) oral solution (Livmarli), Cholbam (cholic acid) capsules, and Chenodal or Ctexli (chenodiol) tablets. Livmarli is an orally administered, minimally-absorbed ileal bile acid transporter (IBAT) inhibitor (IBATi) that is used for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS) in the United States and various other countries and for cholestatic pruritus in patient with progressive familial intrahepatic cholestasis (PFIC) in the United States. Cholbam is used for the treatment of bile acid synthesis disorders due to single enzyme deficiencies and adjunctive treatment of peroxisomal disorders. The Company is also advancing its product candidate, volixibat, for the treatment of adult patients with cholestatic liver diseases.

arrow icon

What is the price predicton of MIRM Stock?

Wall Street analysts forecast MIRM stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for MIRM is 69.13 USD with a low forecast of 53.00 USD and a high forecast of 77.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Mirum Pharmaceuticals Inc (MIRM)'s revenue for the last quarter?

Mirum Pharmaceuticals Inc revenue for the last quarter amounts to 111.59M USD, increased 61.20 % YoY.

arrow icon

What is Mirum Pharmaceuticals Inc (MIRM)'s earnings per share (EPS) for the last quarter?

Mirum Pharmaceuticals Inc. EPS for the last quarter amounts to -0.30 USD, decreased -44.44 % YoY.

arrow icon

What changes have occurred in the market's expectations for Mirum Pharmaceuticals Inc (MIRM)'s fundamentals?

The market is revising Upward the revenue expectations for Mirum Pharmaceuticals, Inc. (MIRM) for FY2025, with the revenue forecasts being adjusted by 2.29% over the past three months. During the same period, the stock price has changed by 28.36%.
arrow icon

How many employees does Mirum Pharmaceuticals Inc (MIRM). have?

Mirum Pharmaceuticals Inc (MIRM) has 322 emplpoyees as of July 08 2025.

arrow icon

What is Mirum Pharmaceuticals Inc (MIRM) market cap?

Today MIRM has the market capitalization of 2.50B USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerCrypto Technical AnalysisAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings Trading
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySitemap
Start for Free